Silence Therapeutics Launches $150M Offering at 26% Discount After Phase 2 Win
SLN has more than doubled off its 52-week low of $4.19 on elevated volume (23× avg).
Summary
Just hours after reporting positive Phase 2 data for divesiran, Silence Therapeutics launched a $150 million underwritten ADS offering at $11.95 per share—a 26% discount to the current price. The raise extends the cash runway into 2029 but dilutes existing holders.
Updates
· SEC S-3MEF — The offering was upsized by $40 million to $190 million, including the underwriters' option to purchase additional ADSs.
Key Events · Financing and Capital Events · SLN
-
$150M Underwritten Offering Launched
An underwritten public offering of ADSs is underway, targeting $150 million with an option for underwriters to purchase additional shares. The deal is priced at $11.95 per ADS, the closing price on August 7, 2026.
-
26% Discount to Current Price
At $11.95, the offering price represents a 26% discount to today's stock price of $16.19, reflecting a deep concession to secure rapid funding on the heels of positive Phase 2 data.
-
Cash Runway Extended into 2029
Together with existing cash, the net proceeds are expected to fund operations into 2029, covering the planned Phase 3 trial for divesiran and other pipeline programs.
-
Immediate Dilution for Existing Shareholders
The offering will cause immediate dilution. Based on 47.2 million ADSs outstanding, the $150 million raise at $11.95 implies roughly 12.5 million new ADSs, or about 26% dilution.
Analysis · SLN · Life Sciences
Hours after reporting blockbuster Phase 2 data for divesiran in polycythemia vera—where 88% of treated patients hit the primary endpoint—Silence Therapeutics is raising $150 million in an underwritten public offering. The deal is priced at $11.95 per ADS, a 26% discount to today's $16.19 price. While the positive data lifted the stock, the deeply discounted raise signals an urgency to capitalize on the momentum and lock in funding. Net proceeds, combined with existing cash, are expected to carry operations into 2029, covering the planned Phase 3 trial. Existing shareholders face immediate dilution, but the capital removes near-term financing risk and strengthens the balance sheet for pivotal development.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLN was trading at $16.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $564.5M. The 52-week trading range was $4.19 to $17.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.